Stockscreener 앱 받기
124.22
0.86%
-1.07
전일 마감가:
$125.29
열려 있는:
$124.7
하루 거래량:
2.90M
Relative Volume:
0.47
시가총액:
$216.04B
수익:
$43.84B
순이익/손실:
$13.90B
주가수익비율:
15.58
EPS:
7.9725
순현금흐름:
$6.92B
1주 성능:
-0.50%
1개월 성능:
-1.67%
6개월 성능:
-7.38%
1년 성능:
+9.50%
1일 변동 폭
$123.64
$125.25
1주일 범위
$123.64
$126.24
52주 변동 폭
$110.86
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
124.24 | 217.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
94.75 | 141.35B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
348.43 | 134.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.37 | 123.15B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.08 | 49.47B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
The Truth About Abbott Laboratories: Is This ‘Boring’ Stock Actually a Secret Power Play? - AD HOC NEWS
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Allspring Global Investments Holdings LLC Acquires 69,578 Shares of Abbott Laboratories $ABT - MarketBeat
Bank Pictet & Cie Europe AG Has $9.82 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature - FinancialContent
Mather Group LLC. Raises Position in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Acquires 20,035 Shares of Abbott Laboratories $ABT - MarketBeat
With EPS Growth And More, Abbott Laboratories (NYSE:ABT) Makes An Interesting Case - Yahoo Finance
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings? - TradingView — Track All Markets
The Truth About Abbott Laboratories: Viral Hype Or Boring Boomer Stock You’re Sleeping On? - AD HOC NEWS
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance Singapore
Shum Financial Group Inc. Acquires Shares of 8,127 Abbott Laboratories $ABT - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 245,400 Shares of Abbott Laboratories $ABT - MarketBeat
Brendel Financial Advisors LLC Sells 23,978 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus - ts2.tech
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment - Finviz
Traders Buy Large Volume of Call Options on Abbott Laboratories (NYSE:ABT) - MarketBeat
Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger - The Globe and Mail
Oak Harvest Investment Services Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Diversified Trust Co Boosts Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Walks a Tightrope Between Defensive Haven and Growth Re?Rating - AD HOC NEWS
U.S. Embolic Protection Devices Market and Competition - GlobeNewswire
U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More - Yahoo Finance
Ethic Inc. Has $29.96 Million Position in Abbott Laboratories $ABT - MarketBeat
Tealwood Asset Management Inc. Grows Stock Position in Abbott Laboratories $ABT - MarketBeat
Rede Wealth LLC Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Pacer Advisors Inc. - MarketBeat
Is AbbVie a Buy, Sell, or Hold in 2026? - The Motley Fool
Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Abbott Laboratories $ABT Shares Acquired by Brookstone Capital Management - MarketBeat
What you need to know ahead of Abbott Laboratories' earnings release - MSN
V. M. Manning & CO. Inc. Makes New $2.70 Million Investment in Abbott Laboratories $ABT - MarketBeat
What You Need to Know Ahead of Abbott Laboratories' Earnings Release - Yahoo Finance
Abbott Laboratories Pakistan : Corporate Briefing Session 2025 - marketscreener.com
Abbott Laboratories $ABT Shares Sold by Covea Finance - MarketBeat
Avanza Fonder AB Purchases 10,889 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms - ts2.tech
Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26 - ts2.tech
Abbott Laboratories Shrugs Off Tariffs & China Headwinds With 7% Dividend Raise (NYSE:ABT) - Seeking Alpha
Swedbank AB Sells 179,009 Shares of Abbott Laboratories $ABT - MarketBeat
Vontobel Holding Ltd. Sells 1,389,990 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by IFM Investors Pty Ltd - MarketBeat
GLOBALT Investments LLC GA Boosts Stock Position in Abbott Laboratories $ABT - MarketBeat
DAVENPORT & Co LLC Has $127.05 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open - ts2.tech
Abbott Laboratories (ABT) director Nita Ahuja files Form 3 with no securities owned - Stock Titan
Abbott India Limited (NSE:ABBOTINDIA) stock most popular amongst public companies who own 75%, while individual investors hold 17% - simplywall.st
Abbott Stock May Benefit Following Volt PFA's FDA Approval - Nasdaq
Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns? - Yahoo Finance
This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now? - Yahoo Finance
Abbott Wins FDA Clearance for Volt - Yahoo Finance
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
0.34%
자본화:
|
볼륨(24시간):